콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

D9641

Sigma-Aldrich

Deoxygalactonojirimycin hydrochloride

powder or solid, ≥98% (HPLC)

동의어(들):

1,5-Dideoxy-1,5-imino-D-galactitol, Migalastat

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C6H13NO4 · HCl
CAS Number:
Molecular Weight:
199.63
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.32

product name

Deoxygalactonojirimycin hydrochloride,

생물학적 소스

synthetic (organic)

Quality Level

분석

≥98% (HPLC)

형태

powder or solid

solubility

water: soluble 1 mg/mL

저장 온도

−20°C

SMILES string

Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O

InChI

1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5+,6-;/m1./s1

InChI key

ZJIHMALTJRDNQI-OLALXQGDSA-N

애플리케이션

Deoxygalactonojirimycin hydrochloride has been used as an α-galactosidase A inhibitor to assess the enzymatic activity of α-galactosidase A. It has also been used as an α-galactosidase A inhibitor to study its effects on the mRNA levels in human embryonic kidney (HEK) cells and hippocampal neurons.

생화학적/생리학적 작용

Deoxygalactonojirimycin hydrochloride is an inhibitor of α-galactosidase A. Deoxygalactonojirimycin exhibits therapeutic effects against Fabry disease.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

개인 보호 장비

dust mask type N95 (US), Eyeshields, Gloves


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Libia Catalina Salinas Castellanos et al.
Neurochemistry international, 140, 104824-104824 (2020-08-26)
Neuropathic pain is one of the key features of the classical phenotype of Fabry disease (FD). Acid sensing ion channels (ASICs) are H+-gated cation channels, which belong to the epithelial sodium channel/DeGenerin superfamily, sensitive to the diuretic drug Amiloride. Molecular
Anthony Markham
Drugs, 76(11), 1147-1152 (2016-06-29)
Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare
Paulsen, H., et al.
Chemische Berichte, 113, 2601-2601 (1980)
Antonino Tuttolomondo et al.
Oncotarget, 8(37), 61415-61424 (2017-10-06)
Anderson-Fabry disease (AFD) is an inborn lysosomal enzymopathy resulting from the deficient or absent activity of the lysosomal exogalactohydrolase, α-galactosidase A. This deficiency, results in the altered metabolism of glycosphingolipids which leads to their accumulation in lysosomes, thus to cellular
Antonino Tuttolomondo et al.
Clinical biochemistry, 48(1-2), 55-62 (2014-10-05)
Anderson/Fabry disease expresses a wide range of clinical variability in patients that it is possible to explain referring to a genetic variability with numerous mutations described in the literature (more than 600). We report some clinical cases of some members

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.